Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - AVADEL PHARMACEUTICALS PLCv446086_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - AVADEL PHARMACEUTICALS PLCv446086_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - AVADEL PHARMACEUTICALS PLCv446086_ex31-1.htm
10-Q - 10-Q - AVADEL PHARMACEUTICALS PLCv446086_10q.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Flamel Technologies S.A. (the “Company”) for the period ended June 30, 2016 (the “Report”), the undersigned hereby certifies in his capacity as Chief Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

 

1.           the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.           the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 15, 2016 /s/ Michael F. Kanan  
  Michael F. Kanan  
 

Senior Vice President and Chief Financial Officer

(Principal Financial Officer)